Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that distinct alopecia scoring systems measure percent hair loss as a common underlying feature, with strong correlations observed between different types of hair loss assessments.

This study developed and validated an objective dermoscopic severity score for evaluating female pattern hair loss, which may serve as a supplementary outcome measure in therapeutic trials.

This study found that among university students, both low and high zinc levels were associated with significant hair loss, while these zinc concentrations did not significantly impact other health issues like diarrhea, acne, or weight loss.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.

This case report suggests that individualized homeopathic therapy with Carcinosin may benefit pediatric patients with alopecia areata by improving hair regrowth and psychological symptoms, as supported by standardized assessment tools.

The researchers reported that an oral supplement containing hydrolysed fish-origin collagen, taurine, cysteine, methionine, iron, and selenium significantly improved the effectiveness of anti-hair loss treatments in people with androgenic alopecia or chronic telogen effluvium after 12 weeks, compared to drug treatments alone.

In this study, the researchers found that rare genetic variants make a minor contribution to male-pattern hair loss risk, identifying five significant gene associations, including novel genes, and noting a shared basis with monogenic hair loss disorders.

This study reviewed data from three hospitals and found that alopecia after DRESS occurred more often in severe cases, but the rate of corticosteroid treatment did not significantly differ between patients with and without alopecia.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

Hair restoration is advancing with new treatments and needs collaboration across fields for effective, evidence-based care.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

In this study, centralised measurements provided more consistent and accurate results for assessing hair loss in mild-to-moderate alopecia areata, reducing error compared to local ratings.

This study found that healthcare professionals, particularly dermatologists, can enhance their impact on social media by actively engaging across platforms and leveraging features like "Duet" or "Remix" to combat misinformation, highlighting their important role in optimizing public education on medical topics in a digital age.

Scalp micro-wounding helps promote hair growth in female pattern hair loss.

This study found that women with Female Pattern Hair Loss had lower serum BDNF levels, which correlated with higher stress and depression, suggesting BDNF as a potential marker for psychological impacts in these patients.

In this study, purebred Dexter cows with higher levels of winter hair shedding weaned heavier calves and had better reproductive success compared to cows with lower shedding levels.

This study found that oral baricitinib treatment led to hair regrowth in patients with alopecia areata, as observed in two phase 3 trials.

This review suggests a shift toward genetically informed treatments for male pattern hair loss by integrating genetic insights and pharmacogenetic markers into therapeutic decision-making.

This study found that oral spironolactone improved or maintained hair condition in females with scarring alopecia and female pattern hair loss, with 83% of patients tolerating the treatment well, despite some side effects like hyperkalemia and leg cramps.

This study found that after 15 months of treatment with ritlecitinib, patients with alopecia areata and less than 95% initial hair loss experienced significant hair regrowth, though those with more extensive hair loss showed more variable improvement.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

This review discusses vaccine safety concerns for individuals with autoimmune and inflammatory conditions, noting vaccine hesitancy due to observed exacerbations post-vaccination and a lack of comprehensive trial data.

This study evaluated microneedling's effect on hair loss, finding a minor reduction in SALT scores for androgenetic alopecia patients, but no significant change for fibrosing or alopecia areata groups. Further skin biopsy analyses are pending to explore other changes beyond SALT scores.

In this study, a serum containing Silybum marianum extract, Manganese PCA, and Lespedeza capitata extract improved hair growth and prolonged the anagen phase in a human scalp skin model.

Adding a cosmetic gel with caffeine, taurine, and growth factors to standard hair loss treatments could improve results.

Low quality of life and high HSS-29 scores increase risk of losing patients during treatment.

The FDA approved a new Pfizer drug for hair loss in teens.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.